CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents

Area of Science:

• Immunology
• Molecular Biology
• DNA Therapeutics

Background:

• CpG DNA (cytosine-guanine dinucleotides) are known immune stimulants.
• Traditional CpG DNA requires specific hexameric motifs for immune activation.
• Optimal CpG DNA sequences often differ between murine and human immune cells.

Purpose of the Study:

• To develop novel, short DNA sequences with potent immunomodulatory activity.
• To investigate if these short sequences can activate immune responses without conventional motifs.
• To evaluate their potential in treating Th2-mediated conditions and inhibiting tumor growth.

Main Methods:

• Design and synthesis of short DNA sequences (5-6 nucleotides) linked via 3'-3' linkages.
• Assessment of cytokine secretion (IL-12, IL-6, IFN-gamma) in murine spleen cells and human PBMCs.
• In vivo studies including splenomegaly assessment and tumor xenograft inhibition.
• Analysis of NF-kappaB and stress-activated signaling pathways.

Main Results:

• Short-immunomers demonstrated potent IL-12 and IL-6 secretion in murine and human cells.
• These sequences activated NF-kappaB and stress-activated pathways, inducing cytokines.
• Short-immunomers reversed Th2 to Th1 responses and inhibited tumor growth in vivo.
• Activity was observed without the conventional -PuPu(Py)CGPyPy- hexameric motif.

Conclusions:

• Novel short DNA sequences (short-immunomers) are potent immune stimulants, independent of traditional motifs.
• Short-immunomers exhibit broad applicability across murine and human cells and therapeutic potential.
• This study introduces a new class of immunomodulatory DNA with significant therapeutic implications.